Liraglutide and Cardiometabolic Effects: More than Just Another Antiobesity Drug?

Curr Vasc Pharmacol. 2016;14(1):76-9. doi: 10.2174/157016111401151126161741.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Female
  • Glucagon-Like Peptide 1 / analogs & derivatives*
  • Humans
  • Hypoglycemic Agents / administration & dosage*
  • Male
  • Obesity / drug therapy*

Substances

  • Hypoglycemic Agents
  • Glucagon-Like Peptide 1